<b>Clinical effect observation of apatinib combined with 131I for radioiodine-refractory differentiated thyroid cancer and prognostic significance analysis of MIP-1α after treatment</b>

One hundred and six patients with RAIR-DTC admitted to our hospital from January 2019 to October 2020 were selected for the study. All the patients were treated with TC surgery with 131I at our hospital, and 58 of them were subsequently transferred to AP treatment, which was considered as the research group; the other 48 patients were transferred to TSH suppression treatment, which was considered as the control group.